Rice University
Rice University, established in 1912 and located in Houston, Texas, is a private research institution primarily focused on undergraduate education. The university comprises eleven residential colleges and eight academic schools, including the Wiess School of Natural Sciences and the George R. Brown School of Engineering. It offers graduate programs through various schools, such as the Jesse H. Jones Graduate School of Business and the School of Architecture. Rice is recognized for its strong emphasis on applied science, particularly in fields such as artificial heart research and nanotechnology, and it has received accolades for its materials science research. The university enforces a strict Honor Code through a student-run Honor Council, fostering a culture of integrity. With approximately 3,900 undergraduates and 2,600 graduate students from diverse backgrounds, Rice University is a member of the Association of American Universities and is noted for its entrepreneurial activities and business incubation efforts.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.